HK1215437A1 - 羧基取代的咪唑並 吡啶甲醯胺及其作爲可溶性鳥苷酸環化酶的刺激物的用途 - Google Patents

羧基取代的咪唑並 吡啶甲醯胺及其作爲可溶性鳥苷酸環化酶的刺激物的用途

Info

Publication number
HK1215437A1
HK1215437A1 HK16103467.0A HK16103467A HK1215437A1 HK 1215437 A1 HK1215437 A1 HK 1215437A1 HK 16103467 A HK16103467 A HK 16103467A HK 1215437 A1 HK1215437 A1 HK 1215437A1
Authority
HK
Hong Kong
Prior art keywords
pyridinecarboxamides
carboxy
guanylate cyclase
soluble guanylate
substituted imidazo
Prior art date
Application number
HK16103467.0A
Other languages
English (en)
Inventor
Alexandros Vakalopoulos
Ingo Hartung
Markus Follmann
Rolf Jautelat
Alexey Gromov
Niels Lindner
Dirk Schneider
Frank Wunder
Johannes-Peter Stasch
Gorden Redlich
Volkhart Min-Jian Li
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1215437A1 publication Critical patent/HK1215437A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
HK16103467.0A 2012-11-05 2016-03-24 羧基取代的咪唑並 吡啶甲醯胺及其作爲可溶性鳥苷酸環化酶的刺激物的用途 HK1215437A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12191202 2012-11-05
US13/789,414 US8796305B2 (en) 2012-11-05 2013-03-07 Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
PCT/EP2013/072881 WO2014068095A1 (de) 2012-11-05 2013-11-04 Carboxy-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung als stimulatoren der löslichen guanylatcyclase

Publications (1)

Publication Number Publication Date
HK1215437A1 true HK1215437A1 (zh) 2016-08-26

Family

ID=47088759

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103467.0A HK1215437A1 (zh) 2012-11-05 2016-03-24 羧基取代的咪唑並 吡啶甲醯胺及其作爲可溶性鳥苷酸環化酶的刺激物的用途

Country Status (7)

Country Link
US (1) US8796305B2 (zh)
EP (1) EP2914595A1 (zh)
JP (1) JP2015535271A (zh)
CN (1) CN104955823B (zh)
CA (2) CA2890155A1 (zh)
HK (1) HK1215437A1 (zh)
WO (1) WO2014068095A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
ES2625744T3 (es) 2013-06-04 2017-07-20 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]piridinas sustituidas con 3-arilo y su uso
JP2016539166A (ja) * 2013-12-05 2016-12-15 バイエル・ファルマ・アクティエンゲゼルシャフト アリール−およびヘテロアリール置換イミダゾ［１，２−ａ］ピリジン−３−カルボキサミドおよびその使用
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
US9688699B2 (en) 2014-02-19 2017-06-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
CN106715426A (zh) 2014-03-21 2017-05-24 拜耳医药股份有限公司 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途
US20170050961A1 (en) * 2014-05-02 2017-02-23 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases
CA2969268A1 (en) 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
EP3227286B1 (de) * 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
WO2016124565A1 (de) 2015-02-05 2016-08-11 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridin-3-carboxamide und ihre verwendung
EP3291811B1 (en) 2015-05-06 2019-08-07 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
SI3325013T2 (sl) 2015-07-23 2023-11-30 Bayer Pharma Aktiengesellschaft Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba
EP3389655A2 (en) 2015-12-14 2018-10-24 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
EP3525779A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
SG11202011018PA (en) 2018-05-15 2020-12-30 Bayer Ag 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
MX2021000363A (es) 2018-07-11 2021-04-29 Cyclerion Therapeutics Inc Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
AR117291A1 (es) 2018-12-14 2021-07-28 Syngenta Crop Protection Ag Compuestos heterocíclicos de cianamida con actividad pesticida
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221996A (en) 1986-10-07 1989-08-29 Yamanouchi Pharma Co Ltd Imidazo-pyridine derivatives and pharmaceutical compositions
SE8704248D0 (sv) 1987-10-30 1987-10-30 Haessle Ab Medical use
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
JPH07242666A (ja) * 1994-03-08 1995-09-19 Fujisawa Pharmaceut Co Ltd 複素環化合物
WO1996034866A1 (en) 1995-05-01 1996-11-07 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors
CA2196263C (en) 1996-02-09 2004-10-26 Barry Jackson Process for the preparation of 4-oxoimidazolinium salts
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
JP3470692B2 (ja) * 1997-10-09 2003-11-25 小野薬品工業株式会社 アミノブタン酸誘導体
WO1999043673A1 (fr) * 1998-02-26 1999-09-02 Zenyaku Kogyo Kabushiki Kaisha Derives de 1-aza-indolizine
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
CA2568850A1 (en) 2004-08-02 2006-02-16 Schwarz Pharma Ag Indolizine carboxamides and the aza and diaza derivatives thereof
US20100130737A1 (en) * 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
TW201345908A (zh) * 2006-07-05 2013-11-16 Mitsubishi Tanabe Pharma Corp 吡唑并〔１，５-ａ〕嘧啶化合物
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CA2666489C (en) 2006-10-19 2012-10-02 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
DE102006054562A1 (de) 2006-11-20 2008-05-21 Bayer Healthcare Ag Verfahren zum Nachweis von Pyrophosphat mit Biolumineszenz Detektion
CN101631786A (zh) 2006-12-20 2010-01-20 先灵公司 新颖的jnk抑制剂
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SG184073A1 (en) 2010-03-18 2012-10-30 Pasteur Institut Korea Anti-infective compounds
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
CA2817368C (en) * 2010-12-15 2019-12-31 Theravance, Inc. Neprilysin inhibitors
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
EA201391769A1 (ru) * 2011-05-30 2014-04-30 Астеллас Фарма Инк. Имидазопиридиновые соединения
US8778964B2 (en) * 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use

Also Published As

Publication number Publication date
EP2914595A1 (de) 2015-09-09
CN104955823B (zh) 2017-04-19
US8796305B2 (en) 2014-08-05
CA2890155A1 (en) 2014-05-08
US20140128425A1 (en) 2014-05-08
CN104955823A (zh) 2015-09-30
WO2014068095A1 (de) 2014-05-08
JP2015535271A (ja) 2015-12-10
CA2910144A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
HK1215437A1 (zh) 羧基取代的咪唑並 吡啶甲醯胺及其作爲可溶性鳥苷酸環化酶的刺激物的用途
HK1212335A1 (zh) 羥基取代的咪唑並 吡啶甲酰胺及其作爲可溶性鳥苷酸環化酶刺激劑的用途
HK1216174A1 (zh) 氨基取代的咪唑並 吡啶羧酰胺和它們的用途
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
HK1221469A1 (zh) -芳基-取代的咪唑並 吡啶及其用途
ZA201406148B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
HK1213558A1 (zh) 作為成像劑的 -苯基咪唑並 嘧啶
ZA201400050B (en) Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
IL227496B (en) Pyrazolo[4,3–b]pyridines are converted as drugs
IL233863A (en) Pyridine derivatives, preparations containing them and their uses
PT2600719E (pt) 8 ¿ alquilo -2 - substituído 7 ¿ oxo ¿ 7,8 ¿ diidropirido [2,3 ¿ d] pirimidina ¿ 6 ¿ carbonitrilos e seus usos
IL222977A0 (en) Novel 3,5- disubstituted-3 h-imidazolo[5-b]pyridine and 3,5-disubstituted-3h-[1.2.3]triazolo[4,5]py
IL221207A0 (en) Pyrazolo piperidine derivatives, compositions comprising the same and uses thereof
IL221209A0 (en) Pyrazolo piperidine derivatives, compositions comprising the same and uses thereof
HK1220201A1 (zh) 作爲成像工具的咪唑並 吡啶- -胺類
IL221479A0 (en) Triazolo [4,5-b] pyridin derivatives
EP2565194A4 (en) Imidazo [1,2-A] pyridine
HK1221457A1 (zh) 種吡嗪並 吲哚化合物及其製備方法和在藥物中的應用
HK1205504A1 (zh) 取代的吡唑並 吡啶、其製備及作為藥物的應用
HK1221458A1 (zh) 種吡嗪並 吲哚化合物及其製備方法和在藥物中的應用

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211031